Who are Para-Toluenesulfonamide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Para-Aminosalicylic Acid, Co-trimoxazole 12, Trimethoprim and sulfamethoxazole, Co-trimoxazole 20, TMX-SMX (Bactrim(R)), Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/para-toluenesulfonamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Para-Toluenesulfonamide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Para-Toluenesulfonamide (Para-Toluenesulfonamide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonamide antibiotic. Area: Infectious disease.

phase 3 Sulfonamide antibiotic dihydropteroate synthetase Infectious disease Small molecule Live · refreshed every 30 min

Target snapshot

Para-Toluenesulfonamide (Para-Toluenesulfonamide) — Gongwin Biopharm Co., Ltd.. Para-Toluenesulfonamide is a sulfonamide antibiotic that inhibits bacterial growth by disrupting folic acid synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Para-Toluenesulfonamide TARGET	Para-Toluenesulfonamide	Gongwin Biopharm Co., Ltd.	phase 3	Sulfonamide antibiotic	dihydropteroate synthetase
Para-Aminosalicylic Acid	Para-Aminosalicylic Acid	Beijing Chest Hospital	phase 3	Bacteriostatic antibiotic	Dihydropteroate synthetase
Co-trimoxazole 12	Co-trimoxazole 12	Khon Kaen University	marketed	Sulfonamide antibiotic combination	Dihydropteroate synthase and dihydrofolate reductase
Trimethoprim and sulfamethoxazole	Trimethoprim and sulfamethoxazole	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Sulfonamide antibiotic combination	Dihydropteroate synthase and dihydrofolate reductase
Co-trimoxazole 20	Co-trimoxazole 20	Khon Kaen University	marketed	Sulfonamide antibiotic combination	Dihydropteroate synthase and dihydrofolate reductase
TMX-SMX (Bactrim(R))	TMX-SMX (Bactrim(R))	Department of Medical Services Ministry of Public Health of Thailand	marketed	Sulfonamide antibiotic combination	Dihydrofolate reductase; dihydropteroate synthase
Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]	Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim]	Fundacion Clinic per a la Recerca Biomédica	marketed	Sulfonamide antibiotic combination	Dihydropteroate synthase and dihydrofolate reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonamide antibiotic class)

Gongwin Biopharm Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Para-Toluenesulfonamide — Competitive Intelligence Brief. https://druglandscape.com/ci/para-toluenesulfonamide. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab